MedTrace Logo

Phenotype and Prognosis of Patients With Breast Cancer and Pathogenic Variants of TP53

NCT04966923 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 135

Last updated 2022-08-09

No results posted yet for this study

Summary

A prospective and retrospective cohort study of patients with a documented pathogenic or likely pathogenic variants of TP53 were identified using blood DNA colection and breast cancer diagnosis by histological confirmation, between 1999 and 2022. All patients were followed by the Hereditary Group of a single cancer center (Instituto do Cancer do Estado de Sao Paulo). Patients were included if they had a histopathological diagnosis of localized invasive carcinoma or in situ carcinoma of the breast and with localized disease. Patients met Revised Chompret criteria, Li Fraumeni like syndrome,family member of carrier TP53 or hereditary breast and ovarian syndrome for germline test.

Conditions

  • Breast Cancer
  • TP53 R337H
  • Li-Fraumeni Syndrome
  • Prognosis Breast Cancer

Interventions

OTHER

No intervention in this study

Analyses of pathogenic variant TP53 and variants in genetic test

Sponsors & Collaborators

  • Instituto do Cancer do Estado de São Paulo

    lead OTHER

Principal Investigators

  • Vanessa Petry, MD · Instituto do Cancer do Estado de São Paulo

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-02
Primary Completion
2021-08-07
Completion
2022-02-22

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04966923 on ClinicalTrials.gov